Related Experiment Video

Updated: May 2, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

13.0K

Seeing the forest for the trees: kidney oncogenomes in relation to therapeutic outcomes

David D Chism1, W Kimryn Rathmell

  • 1Authors' Affiliation: Division of Hematology and Oncology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|March 18, 2014
PubMed

Insights

Investigating rare responders to rapalogs in renal cell carcinoma revealed genetic mutations. These findings in TSC1 and mTOR genes offer new insights into tumor evolution and treatment strategies.

Area of Science:

  • Oncology
  • Genetics
  • Molecular Biology

Background:

  • Renal cell carcinoma (RCC) is a complex cancer with varied responses to treatment.
  • Identifying biomarkers for predicting treatment efficacy is crucial for personalized medicine.

Purpose of the Study:

  • To investigate the genetic underpinnings of exceptional response to rapalogs in renal cell carcinoma.
  • To explore potential therapeutic targets and understand tumor evolution in treatment responders.

Main Methods:

  • Oncogenomic analysis was performed on a cohort of five patients with sustained response to rapalogs.
  • Genetic sequencing and data analysis were employed to identify key mutations.

Main Results:

  • Alterations in the TSC1 and mTOR genes were implicated in the sustained response observed in these patients.
  • These genetic findings provide insights into the molecular mechanisms driving treatment sensitivity.

Conclusions:

  • The study highlights the role of TSC1 and mTOR gene alterations in predicting response to rapalogs in a subset of renal cell carcinoma patients.
  • Understanding these genetic drivers can inform future therapeutic strategies for renal cell carcinoma.

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

7.1K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

6.5K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K